

DOCKET NO.: B0801.70231US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lee et al.  
Serial No.: 10/024,607  
Confirmation No.: 6830  
Filed: November 8, 2001  
For: CARDIOVASCULAR DISEASE DIAGNOSTIC AND  
THERAPEUTIC TARGETS  
Examiner: Bruce D. Hissong  
Art Unit: 1646

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on January 29, 2007.

  
Nicole Millette Hawes

---

**MAIL STOP RCE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF  
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement is being filed with a request for continued examination under 37 C.F.R. §1.114.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.


Serial No.: 10/024,607  
Conf. No.: 6830

- 3 -

Art Unit: 1646

An early and favorable action is hereby requested.

Respectfully submitted,

  
\_\_\_\_\_  
Janice A. Watland, Ph.D., Reg. No. 52,318  
Wolfe, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2206  
Telephone: (617) 646-8000

Docket No.: B0801.70231US00  
Date: January 29, 2007  
x01.27.07

FORM PTO-1449/A and B (Modified PTO/SB/08) <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			APPLICATION NO.: 10/024,607	ATTY. DOCKET NO.: B0801.70231US00	
			FILING DATE: November 8, 2001	CONFIRMATION NO.: 6830	
			APPLICANT: Lee et al.		
			GROUP ART UNIT: 1646	EXAMINER: Bruce D. Hissong	
Sheet	1	of	2		

#### U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
/BH/	A6	6,323,334		Kingsbury et al.	11-27-2001
/BH/	A7	2006-0216755		Lee	09-28-2006

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
/BH/	C64	[No Author Listed] Information Hyperlinked Over Proteins – Symbol IL1RL1. <a href="http://www.ihop-net.org/UniPub/iHOP/gismo/94438.html?ORGANISM ID=1">http://www.ihop-net.org/UniPub/iHOP/gismo/94438.html?ORGANISM ID=1</a> .	
↓	C65	ALBERT et al., Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation. 2002 Jun 4;105(22):2595-9.	
↓	C66	AUER et al., C-reactive protein and coronary artery disease. Jpn Heart J. 2002 Nov;43(6):607-19.	
↓	C67	FELDMAN et al., C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr. 2003 Feb 1;32(2):210-4. Abstract Only.	
↓	C68	FORSSMANN et al., The heart is the center of a new endocrine, paracrine, and neuroendocrine system. Arch Histol Cytol. 1989;52 Suppl:293-315. Abstract Only.	
↓	C69	HEESCHEN et al., Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol. 2000 May;35(6):1535-42. Abstract Only.	

EXAMINER:	DATE CONSIDERED:
/Bruce Hissong/	07/21/2008

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/024,607		ATTY. DOCKET NO.: B0801.70231US00		
				FILING DATE: November 8, 2001		CONFIRMATION NO.: 6830		
				APPLICANT: Lee et al.				
				GROUP ART UNIT: 1646		EXAMINER: Bruce D. Hissong		
Sheet	2	of	2					

/BH/	C70	JANUZZI et al., Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006 Feb 13;166(3):315-20.	
↓	C71	KIDA et al., [Pathophysiologic role of natriuretic peptides] Rinsho Byori. 1989 Aug;37(8):875-82. Japanese. Abstract Only.	
↓	C72	LAMMERDING et al., Mechanotransduction in cardiac myocytes. Ann N Y Acad Sci. 2004 May;1015:53-70.	
↓	C73	MACKENNA et al., Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc Res. 2000 May;46(2):257-63.	
↓	C74	MUKOYAMA et al., Augmented secretion of brain natriuretic peptide in acute myocardial infarction. Biochem Biophys Res Commun. 1991 Oct 15;180(1):431-6. Abstract Only.	
↓	C75	SUSSMAN et al., Dance band on the Titanic: biomechanical signaling in cardiac hypertrophy. Circ Res. 2002 Nov 15;91(10):888-98.	
↓	C76	VAN KIMMENADE et al., Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006 Sep 19;48(6):1217-24.	
↓	C77	ZEBRACK et al., Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol. 2002 Jan 15;89(2):145-9.	

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
/Bruce Hissong/	07/21/2008

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.